Celladon to Report Fourth Quarter and Fiscal 2014 Results on March 31
March 25 2015 - 4:04PM
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology
company with industry-leading expertise in the development of
cardiovascular gene therapy, today announced that it will report
its results for the fourth quarter and fiscal year ended December
31, 2014 on Tuesday, March 31, 2015. The company will issue a press
release before the market opens and host a live investor conference
call and webcast at 8:30am Eastern/5:30am Pacific.
Conference Call & Webcast
Tuesday, March 31, 2015 @ 8:30am Eastern Time/5:30am
Pacific Time
Domestic: |
855-455-6053 |
International: |
484-756-4307 |
Conference ID: |
15112783 |
Webcast: |
http://ir.celladon.com/events.cfm |
|
|
Replays – Available through April
14, 2015 |
Domestic: |
855-859-2056 |
International: |
404-537-3406 |
Conference ID: |
15112783 |
About Celladon
Celladon is a clinical-stage biotechnology company applying its
leadership position in the field of cardiovascular gene therapy to
develop novel therapies for diseases with tremendous unmet medical
needs. Our lead programs target SERCA enzymes which are a family of
enzymes that play an integral part in the regulation of
intra-cellular calcium in all human cells. Calcium dysregulation is
implicated in a number of important and complex medical conditions
and diseases, such as heart failure, vascular disease, diabetes and
neurodegenerative diseases. MYDICAR, the Company's most advanced
product candidate, uses gene therapy to target SERCA2a, which is an
enzyme that becomes deficient in patients with advanced heart
failure. Celladon has completed enrollment of a 250 patient Phase
2b clinical trial evaluating the efficacy of MYDICAR in reducing
the frequency of, or delaying heart failure-related
hospitalizations. This randomized, double-blind,
placebo-controlled, multinational trial is evaluating a single
intracoronary infusion of MYDICAR versus placebo added to a
maximal, optimized heart failure regimen in patients with New York
Heart Association class III or IV symptoms of chronic heart failure
due to systolic dysfunction. The Company has received Breakthrough
Therapy designation from the FDA for this MYDICAR program and
expects to report results from the Phase 2b clinical trial in late
April 2015. In addition, the Company conducts research and
development on its mSCF gene therapy program for cardiac diseases.
Celladon has also identified a number of potential first-in-class
compounds addressing novel targets in diabetes and
neurodegenerative diseases with its small molecule platform of
SERCA2b modulators. For more information, please visit
www.celladon.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements include, but are not limited to,
statements regarding Celladon's plans to research, develop and
commercialize product candidates, as well as expected timing for
reporting results from clinical trials. Because such statements are
subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. These forward-looking statements are based upon
Celladon's current expectations and involve assumptions that may
never materialize or may prove to be incorrect. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with viral manufacturing processes and
other product development activities, clinical trials and obtaining
regulatory approval to commercialize product candidates, our
reliance on third parties, the need to raise additional funding
when needed in order to conduct our business, and the degree of
market acceptance of MYDICAR by physicians, patients, third-party
payors and others in the medical community. These and other risks
and uncertainties are described more fully in Celladon's filings
with the Securities and Exchange Commission, including without
limitation its Form 10-Q for the quarter ended September 30, 2014.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. Celladon
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
CONTACT: Fredrik Wiklund
Vice President, Corporate Development and Investor Relations
(858) 432-7215
fwiklund@celladon.net
CELLADON CORP (NASDAQ:CLDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
CELLADON CORP (NASDAQ:CLDN)
Historical Stock Chart
From Apr 2023 to Apr 2024